Cargando…

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies in the United States. Improvements in imaging have permitted the categorization of patients according to radiologic involvement of surrounding vasculature, i.e., upfront resectable, borderline resectable, and locally a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sulciner, Megan L., Ashley, Stanley W., Molina, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410260/ https://www.ncbi.nlm.nih.gov/pubmed/36013111 http://dx.doi.org/10.3390/jcm11164866

Ejemplares similares

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented
por: Iordache, Sevastiţa, et al.
Publicado: (2017)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
por: D’Onofrio, Mirko, et al.
Publicado: (2017)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Erratum: The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
Publicado: (2018)

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
por: Barcellini, Amelia, et al.
Publicado: (2020)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
por: Sakaguchi, Tatsuma, et al.
Publicado: (2020)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
por: Vernuccio, Federica, et al.
Publicado: (2021)

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor
por: Pedrazzoli, Sergio
Publicado: (2023)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

Advances in the management of pancreatic ductal adenocarcinoma
por: O’Kane, Grainne M., et al.
Publicado: (2021)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
por: Chouari, Tarak, et al.
Publicado: (2023)

Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma
por: Duconseil, Pauline, et al.
Publicado: (2019)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
por: Franck, Caspar, et al.
Publicado: (2020)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease
por: Kruger, Deirdré, et al.
Publicado: (2022)

Recent advances in precision medicine for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects
por: Jin, Tianqiang, et al.
Publicado: (2020)

Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series
por: Feo, Claudio F., et al.
Publicado: (2021)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3i61h9oohnjoi47nvqml9pfv2r